April 2011

Contents

Editorial

• Volume 12 Number 3/4 March/April 2011

Conference reports

• 18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-–3 March 2011, Boston

• New antiretrovirals: dolutegravir, entry inhibitor (BMS-663068) and tenofovir pro-drug (GS-7340)

• Immune-based treatment increases HIV-resistant CD4 cells in phase 1 study

• Antiretroviral prevention: oral PrEP, gels and treatment studies

• Further efficacy analyses from the iPrEx study

• Topical gels as PEP and PrEP: animal and human studies

• Maternal risk following short course HAART

• Pre-term delivery and HAART

• HAART more effective than AZT monotherapy in the Botswana PMTCT programme

• Lopinavir/r monotherapy for PMTCT

• No evidence of increased risk of MTCT with sequential pregnancies in UK and Ireland

• Recently infected women at the time of delivery have a higher rate of in-utero transmission in PEPI-Malawi

• Reduced CCL22 concentrations in cervicovaginal secretions from pregnant women

• First results from telaprevir in HIV/HCV coinfection

• HCV reinfection rates in HIV-positive gay men

Antiretrovirals

• London HIV Consortium issues new guidelines for ARV prescribing (2011)

• EMA issue restricted indication for d4T (stavudine)

• Changes to starting dose of saquinavir in naive patients

• FDA approve nevirapine XR

• Lopinavir/r oral solution

• Atazanavir use during pregnancy

• Nelfinavir interaction with warfarin

Treatment access

• FDA approval of generic ARVs

• Global Fund reports rise in people on treatment

• UK increases funding to the Global Fund

• UK government development priorities and HIV

• Update on the Patent Pool

• TRIPS agreement flexibilities provide opportunities for improved access to ARVs

• Driving a decade of change: HIV/AIDS, patents and access to medicines for all

Pregnancy

• Lower incidence of pregnancy in HIV positive compared to HIV negative women in the Women’s Interagency HIV Study

Paediatric care

• Long-term outcomes for infants starting lopinavir/ritonavir at less than 6 months

• Effects of antiretroviral exposure through PMTCT strategies on infants in Botswana

PK and drug interactions

• No interaction between raltegravir and oral contraceptives

• Case report: extreme bradycardia with lopinavir/ritonavir and metoprolol and lacidipine

Cure-related research

• Global scientific strategy towards an HIV cure

Basic science and immunology

• Continuing debate over the role of microbial translocation in HIV infection

• Jostling latent HIV from slumber

• Dubious analysis of a therapeutic tat vaccine trial

• Studies on the loss of naive T cells

• Intensifying treatment does not reduce HIV reservoirs, but gut immune responses may have a role to play

BHIVA news

• CROI feedback workshops online

• BASHH/BHIVA PEPSE guidelines for comment (2011)

• UK national guideline on safer sex advice

Other news

• Online European clinical trials registry

On the web

• Guidelines

• Community resources and publications

• Free journal articles

• Medical online resources

PDFs

• Volume 12 Number 3/4 March/April 2011 PDF